921-P: Liraglutide Improves NAFLD in Patients with Type 2 Diabetes

Introduction: The present study was conducted to evaluate the effects of Liraglutide on NAFLD in patients with type 2 diabetes mellitus (T2DM) with elevated transaminases. Methods: A total of 62 patients (male-38, female-24) with age group of 30-75 years, treated with Liraglutide 1.2 mg/1.8 mg OD were included in the study. Selected clinical and demographic profile were recorded for all patients at baseline and follow-up. The hepatic steatosis was assessed using liver elastography (Fibroscan). Results: After a mean follow-up of 26 weeks, in 62 patients (meeting appropriate present inclusion criteria), there was significant reduction in weight from 88.63±8.6 kg (Mean ± SD) to 80.47±6.7 kg (p